AVI BioPharma said this week that it has appointed K. Michael Forrest to its board of directors. Forrest, who is filling the unexpired term of former director Raymond Ruddon, will serve until 2006. Rudden is transitioning to the company’s scientific advisory board.
Forrest was previously CEO of Cellegy Pharmaceuticals. Prior to this, he served in various positions at American Cyanimid and Pfizer.
AVI also announced that Michael Buchmeier, a professor at The Scripps Research Institute, has joined the company’s SAB.
V.W. Brinkerhoff III has been appointed senior vice president and general manager for Gene Logic’s preclinical contract research business, the company said this week.
Prior to joining Gene Logic, Brinkerhoff served in senior management positions at Life Technologies, now Invitrogen.
Sangamo Biosciences said this week that it has appointed Margaret Liu to its board of directors.
Liu has served as senior director at Merck Research Laboratories in the department of virus and cell biology, vice president of vaccines research and gene therapy at Chiron, and senior advisor in vaccinology at the Bill and Melinda Gates Foundation.